Biomarkers /
IGF1R
Overview
Insulin-like growth factor 1 receptor (IGF1R) is a gene that encodes a protein that is a receptor tyrosine kinase that binds insulin-like growth factor. Missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as intestinal cancer, skin cancer, and stomach cancer.
IGF1R is altered in 2.41% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, and cutaneous melanoma having the greatest prevalence of alterations [3].
The most common alterations in IGF1R are IGF1R Mutation (1.86%), IGF1R Amplification (0.50%), IGF1R Loss (0.06%), IGF1R R1246C (0.02%), and IGF1R K560R (0.11%) [3].
Clinical Trials
Significance of IGF1R in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.